A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.

Drew W RascoKyriakos P Papadopoulos Michael PourdehnadAnita K GandhiPatrick R HagnerYan LiXin WeiRajesh ChopraKristen HegeJorge DiMartinoKent Shih

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Avadomide monotherapy demonstrated acceptable safety and favorable pharmacokinetics in patients with solid tumors, NHL, and multiple myeloma. In addition, 3 objective responses were observed in NHL.

Keyphrases

multiple myeloma
endothelial cells
combination therapy
open label
clinical trial
randomized controlled trial
study protocol